MDST Medicsight

RNS Number:7103R
Medicsight Plc
07 April 2008


Press Release                                                     7 April 2008

                                 Medicsight PLC

                        ("Medicsight" or "the Company")

                    New Marketing Partnership with INFINITT


Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, announces a new global partnership with INFINITT, one
of the world's leading medical imaging and picture archiving and communication
systems (PACS) companies.  Combined INFINITT-Medicsight products for the
detection of colorectal cancer will be distributed using INFINITT's global
network of offices in six strategic countries and partners and sales channel
representatives in 20 other countries worldwide.


David Sumner, Chief Executive of Medicsight, said: "I am delighted to announce
this new global partnership with INFINITT, already the PACS market leader in
Korea and growing rapidly in other major markets.  Strategic partnerships such
as this one are a key component of our strategy to build a broad base
distribution channel enabling the Company to penetrate global markets quickly
and thereby move into profitability."


"This is the ideal time for INFINITT to partner with Medicsight." said Sun-Joo
Lee, President and CEO of INFINITT.  "The partnership will enable us to bring
the next generation of INFINITT solutions combined with the CAD and image
analysis solutions of Medicsight to meet the demanding needs of our global
customers."


Dr Se Hyung Kim, Assistant Professor, Department of Radiology, Seoul National
University, also commented: "CT Colonography for the screening of colorectal
cancer is now at the forefront of screening technologies for this potentially
fatal disease.  Partnerships such as that between Medicsight and INFINITT which
deliver cutting edge 3D and CAD technologies to radiologists around the world
are vital to increase the adoption of this very important and life saving
technique."


Medicsight's ColonCAD(TM) software will be integrated into INFINITT's PACS and
3D Rapidia Virtual Colonoscopy workstations.  The latter is a next-generation
colorectal cancer screening tool.  Integration has already commenced and a
successful work-in-progress project was demonstrated at the Radiology Society of
North America (RSNA) meeting in November 2007, the major radiology event of the
year. Medicsight and INFINITT will work together to prepare for a 2008 global
launch campaign.



                                    - ENDS -



For further information:

Medicsight PLC
David Sumner                                   Tel: +44 (0)20 7605 7950
                                               www.medicsight.com

Collins Stewart Europe Limited
Tim Mickley                                    Tel: +44 (0)20 7523 8350
Jonny Sloan                                    Tel: +44 (0)20 7523 8302


Media enquiries:
Abchurch                                       Tel: +44 (0) 20 7398 7700
Ashley Tapp                                    Tel: +44 (0) 20 7398 7718
ashley.tapp@abchurch-group.com
Stephanie Cuthbert                             Tel: +44 (0) 20 7398 7712
stephanie.cuthbert@abchurch-group.com          www.abchurch-group.com



Notes to editors

About Medicsight

Medicsight PLC is a UK-headquartered, research-driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM)
software products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.



About INFINITT

INFINITT Co., Ltd. is one of the world's leading companies in medical imaging
and information management. INFINITT, founded in 1997, develops, manufactures
and markets PACS systems, 3D medical imaging workstations and imaging software
that are now implemented in over 1000 medical institutions in 14 countries,
making the company one of the fastest growing vendors in the global PACS
industry. INFINITT is the market leader in the South Korea PACS market, and is
aggressively pioneering worldwide market expansion through joint ventures in
four strategic regions: Japan, China, Taiwan, and the US, with a branch office
in Malaysia.



About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.



About Medicsight's CAD software

Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.



Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.



Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCIIMRTMMAMBAP

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024